DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ ...

Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines ...

Photodynamic therapy (PDT) resistance limits treatment efficacy in oral leukoplakia (OLK). This study identifies p-NRF2 as a ...

DelveInsight's Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ ...

Leafy greens, such as spinach, kale, Swiss chard, and arugula, are rich in vitamins, minerals, fiber, and antioxidants, ...

Esophageal cancer remains one of the world's deadliest cancers, ranking 7th in incidence and 6th in cancer-related deaths ...

Nuclear factor erythroid 2-related factor 2 (NRF2) is a stress responsive transcription factor that is mutationally activated in a subset (~25%) of clinically-aggressive non-small cell lung cancers ...

A recent study published in Kidney International suggests that nuclear factor-erythroid 2-related factor 2 (Nrf2) activation holds promise as a potential therapeutic strategy for antineutrophil ...

This unchecked cycle can lead to significant health concerns. The synergistic benefits of Protandim ® Nrf2 Synergizer ® and TrueScience ® Liquid Collagen, help break this repetitive stress ...

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce it has completed a pre-Investigational ...